




# Adaptation de la VNI et qualité du sommeil

Olivier Contal, PhD  
[olivier.contal@hesav.ch](mailto:olivier.contal@hesav.ch)

# Sommeil sujet sain



## Architecture du sommeil:


	Duree (min)	% TST	% PST
PST	353		
TST	322		
Eveil intra sommeil	30.4	-	4.2%
Stade 1	9	2.8%	2.7%
Stade 2	137	42.5%	40.8%
Stades 1+2 (SLL)	146	45.3%	43.5%
Stades 3 (SLP)	72.5	22.5%	21.6%
REM	103.6	32.2%	30.8%

## Microstructure du sommeil:

	Total	Index TST
μéveils mouvements	0	0
μéveils respiratoires	2	0.4
Réactions d'éveils non spécifiques	28	5.2



# VNI et sommeil



Contal; Sleep Medicine 2011

# Retentissement de la VNI sur le sommeil

	N	Mean before NIV	Mean after NIV	Difference after and before NIV	P value
Total Sleep Time in min	60	340	343	3	0.82
Sleep efficiency in %	55	64	71	7	0.004
Sleep Latency in min	55	43	28	-15	0.07
REM in min	60	45	66	21	0.005
REM in % of TST	60	12	18	6	0.002
Sleep stage 1 in min	60	73	42	-31	0.001
Sleep stage 1 in % of TST	60	26	14	-12	0.001
Sleep stage 2 in min	60	139	140	1	0.94
Sleep stage 2 in % of TST	60	40	41	1	0.83
SWS in min	55	87	98	11	0.26
SWS in % of TST	55	22	30	8	0.051
Micro Arousal	57	25	14	-11	0.003
Mean of SpO <sub>2</sub> in %	59	85	93	8	< 0.001
Minimum of SpO <sub>2</sub> in %	56	63	77	14	< 0.001
ODI	43	37	13	24	< 0.001

Conti; Sleep Medicine 2011

# VNI au long cours et asynchronie

Variables	Patients With PVA (n = 11)	Patients Without PVA (n = 9)	p Value†
TST, min	379 ± 64	395 ± 66	NS
Sleep efficiency, %	74.1 ± 11.0	69.1 ± 11.0	NS
Stage 1, %	17.6 ± 5.1	12.4 ± 2.2	0.008
Stage 2, %	56.2 ± 9.4	46.2 ± 9.5	0.031
Slow wave sleep, %	15.0 ± 10.0	23.6 ± 8.4	0.05
REM sleep, %	11.3 ± 3.3	17.9 ± 6.9	0.022
AHI, /h	5.1 ± 4.5	5.4 ± 5.9	NS
ODI, /h	7.6 ± 7.5	5.4 ± 5.0	NS
MAI, /h	30 ± 8	21 ± 9	0.032
Minimal Spo <sub>2</sub> , %	79 ± 7	80 ± 6	NS
Mean Spo <sub>2</sub> , %	90 ± 3	91 ± 3	NS
Mean TcPCO <sub>2</sub> , mm Hg	45 ± 6	43 ± 6	NS
Median TcPCO <sub>2</sub> , mm Hg	45 ± 6	44 ± 6	NS

# VNI et FUITES

# VNI et fuites non intentionnelles

	Control	Taped	Delta	p-value
Leak $L \cdot s^{-1}$				
25th centile	0.08±0.01	0.03±0.02	-0.05±0.02	0.05
Median	0.35±0.07	0.06±0.03	-0.29±0.08	0.008
75th centile	0.61±0.08	0.09±0.04	-0.52±0.09	0.0005





Table 3. – Effect of taping mouth on sleep architecture

	Control	Taped	Delta	p-value
Time available for sleep min	372±12	390±9	18±15	0.3
Total sleep time min	309±13	341±18	32±23	0.2
Sleep efficiency % time available	83.1±2.7	86.9±3.2	3.8±3.8	0.3
Sleep latency min	14.2±1.8	12.3±2.1	-1.9±2.3	0.4
Slow wave sleep % sleep time	13.1±1.6	19.5±2.2	6.4±3.4	0.09
REM sleep % sleep time	12.9±1.5	21.1±1.8	8.1±1.8	0.0016

Data are presented as mean±SEM. REM: rapid eye movement.

# Fuites et signaux respiratoires



# Ventilation nocturne avec fuites



VNI – Sommeil - BPCO

# VNI vs O<sub>2</sub> et sommeil

144 patients inclus en ITT BPCO sévère

Randomisés en OLD ou OLD + VNI (69 / 41 analysés)

Compliance VNI > à 4h00

Aide inspiratoire ≥ 5 cmH<sub>2</sub>O

	LTOT	NIV + LTOT	NIV + LTOT
	Baseline	Baseline	NIV treatment
Total sleep time (min)	243 (226 to 260)	249 (231 to 267)	252 (234 to 271)
Sleep efficiency (%)	61.0 (56.8 to 65.2)	59.6 (55.4 to 63.8)	59.7 (55.7 to 63.7)
% NREM	85.0 (83.0 to 87.0)	86.7 (84.6 to 88.8)	82.6 (80.4 to 84.8)*
% REM	15.2 (13.2 to 17.3)	13.3 (11.2 to 15.4)	17.5 (15.3 to 19.7)*
Apnoea-hypopnoea index (events/h)	6.1 (4.8 to 7.5)	4.5 (3.4 to 5.6)	2.8 (1.6 to 4.0)*
T <sub>CO</sub> sleep increase (mm Hg)	18.8 (16.5 to 21.0)	16.5 (14.7 to 18.3)	12.6 (10.9 to 14.3)*
IPAP (cm H <sub>2</sub> O)			12.9 (12.5 to 13.4)
EPAP (cm H <sub>2</sub> O)			5.1 (4.8 to 5.3)

# VNI vs O<sub>2</sub> et sommeil

144 patients inclus en ITT BPCO sévère


Randomisés en OLD ou OLD + VNI (69 / 41 analysés)

Compliance VNI > à 4h00

Aide inspiratoire ≥ 5 cmH<sub>2</sub>O

	LTOT	NIV + LTOT	NIV + LTOT
	Baseline	Baseline	NIV treatment
Total sleep time (min)	243 (226 to 260)	249 (231 to 267)	252 (234 to 271)
Sleep efficiency (%)	61.0 (56.8 to 65.2)	59.6 (55.4 to 63.8)	59.7 (55.7 to 63.7)
% NREM	85.0 (83.0 to 87.0)	86.7 (84.6 to 88.8)	82.6 (80.4 to 84.8)*
% REM	15.2 (13.2 to 17.3)	13.3 (11.2 to 15.4)	17.5 (15.3 to 19.7)*
Apnoea-hypopnoea index (events/h)	6.1 (4.8 to 7.5)	4.5 (3.4 to 5.6)	2.8 (1.6 to 4.0)*
T <sub>CO</sub> sleep increase (mm Hg)	18.8 (16.5 to 21.0)	16.5 (14.7 to 18.3)	12.6 (10.9 to 14.3)*
IPAP (cm H <sub>2</sub> O)			12.9 (12.5 to 13.4)
EPAP (cm H <sub>2</sub> O)			5.1 (4.8 to 5.3)

# VNI et survie



Mc Evoy, Thorax 2009

# Ventilation synchronisée




# Interactions patient-ventilateur et AI

- 8 patients BPCO
- 1<sup>ière</sup> nuit VNI standard
  - EPAP  $5.4 \pm 1.3 \text{ cmH}_2\text{O}$
  - AI  $19 \pm 2 \text{ cmH}_2\text{O}$
- 2<sup>ième</sup> nuit VNI adaptée
  - EPAP  $6.3 \pm 1.8 \text{ cmH}_2\text{O}$
  - AI  $16.5 \pm 2 \text{ cmH}_2\text{O}$



# Cycles non récompensés




# Dyspnée de déventilation





Courtesy D. Adler

# Répercussions de l'adaptation des réglages



# AI élevée et sommeil




# AI élevée et ventilation

		IPAP=14 cmH <sub>2</sub> O	IPAP=30 cmH <sub>2</sub> O	Treatment Effect (95% CI)	P Value
Measure	Period	LI-NPPV	HI-NPPV		
Mean SaO <sub>2</sub> , %	1	87.4 ± 4.6	92.5 ± 1.4	1.3 (-1.1, 3.7)	.27
	2	92.8 ± 1.8	90.3 ± 2.0		
Minimum SaO <sub>2</sub> , %	1	78.3 ± 9.8	85.5 ± 3.4	2.7 (-1.6, 6.9)	.20
	2	86.3 ± 7.0	84.4 ± 5.7		
ODI, events/h <sup>a</sup>	1	2.1 (0.5/26.0)	1.1 (0.6/5.9)	0.76 (0.43, 1.34)	.31
	2	2.0 (0.9/3.8)	1.9 (0.6/5.1)		
SaO <sub>2</sub> < 90%, No. <sup>a</sup>	1	1.3 (2/111)	2.5 (1/11)	0.86 (0.38, 1.92)	.68
	2	1.5 (0/3)	6.0 (0/14)		
Largest decrease in SaO <sub>2</sub> , % <sup>a</sup>	1	6.0 (5/14)	5.5 (4/9)	1.02 (0.63, 1.67)	.92
	2	5.5 (4/6)	7.0 (4/13)		
pH	1	7.35 ± 0.04	7.41 ± 0.04	0.025 (0.004, 0.046)	.025
	2	7.39 ± 0.03	7.38 ± 0.02		
PaO <sub>2</sub> , mm Hg	1	64.0 ± 11.5	75.6 ± 9.9	2.5 (-4.7, 9.8)	.46
	2	73.3 ± 16.8	66.7 ± 12.0		
Paco <sub>2</sub> , mm Hg	1	57.4 ± 12.5	49.3 ± 6.8	-6.4 (-10.9, -1.8)	.010
	2	55.9 ± 7.0	51.3 ± 5.5		
HCO <sub>3</sub> <sup>-</sup> , mmol/L	1	30.7 ± 3.7	30.6 ± 2.9	-1.8 (-3.1, -0.5)	.013
	2	33.1 ± 3.6	29.5 ± 2.8		

VNI – Sommeil - SOH

# VNI et SOH




Borel, Chest 2012

# VNI et SOH


Characteristic	Control Group (n = 18)		NIV Group (n = 19)
Sex, % male	41		44
Age, y	54 ± 6		58 ± 11 <sup>a</sup>
BMI, kg/m <sup>2</sup>	39.6 ± 4.5		39.6 ± 6.3
Hypertension, %	77		89
Myocardial infarction, %	12		0
Type 2 diabetes, %	35		56

Parameter	Baseline		Treatment Period Effect		
	Control Mean ± SD	NIV Mean ± SD	Control Mean Difference (95% CI)	NIV Mean Difference (95% CI)	P Value
TST, min	339 ± 60	372 ± 66 <sup>a</sup>	13.3 (-10.5 to 45.2)	-13.8 (-47.3 to 19.7)	ns
SL1-2, % TST	67 ± 18	77 ± 8	5.7 (-2.8 to 14.2)	-11.8 (-18.5 to -5.1)	.002
SL3-4, % TST	8 ± 17	6 ± 8	-4.3 (-11.7 to 3.1)	3.1 (-1.8 to 7.9)	ns
REM, % TST	24 ± 7	17 ± 6 <sup>b</sup>	-1.6 (-7.3 to 4.1)	8.7 (4.3 to 13.0)	.004
Res µaro, No./h	48 ± 32	37 ± 28	7.2 (-7.3 to 21.6)	-31.2 (-43.9 to -18.5)	<.001
N-Res µaro, No./h	7 ± 9	8 ± 10	-2.5 (-7.2 to 2.2)	6.9 (0.8 to 12.9)	.003
AHI, No./h	54.1 ± 45.6	39.6 ± 37.1	6.3 (-7.9 to 20.4)	-34.1 (-51.7 to -16.5)	<.001
Nadir Spo <sub>2</sub> , %	68.8 ± 16.5	70.4 ± 16.6	-0.6 (-6.0 to 4.7)	10.3 (-1.5 to 22.1)	.001
Mean Spo <sub>2</sub> , %	91.0 ± 4.7	89.3 ± 4.2	-0.6 (-1.9 to 0.7)	4.4 (2.7 to 6.1)	<.001
Spo <sub>2</sub> < 90%, % TST	26.8 ± 29.4	36.7 ± 35.0	3.4 (-3.8 to 10.7)	-32.5 (-49.6 to -15.4)	<.001
ESS	13.1 ± 3.4	11.4 ± 5.6	-2.1 (-4.5 to 0.4)	-3.4 (-6.0 to -0.8)	ns




# Événements centraux et mixtes

Événements respiratoires survenus sous VNI au cours des 3 nuits consécutives avec un mode “S”, en mode “S/T” bas et en mode “S/T” haut.



A: Central events (N/hour)




B: Mixed events (N/hour)

# Résultats de l'étude du sommeil pour les 3 réglages différents de la FR

	No BURR Median [IQR]	Low BURR Median [IQR]	High BURR Median [IQR]	p
TST (min)	413 [345;478]	445 [420;511]	425 [284;464]	0.273
Sleep efficiency (%)	73 [60;82]	83 [73;87]	71 [67;142]	0.273
WASO	134 [81;192]	81 [71;151]	142 [67;206]	0.905
Sleep latency (min)	20 [9;33] ¶	4 [1;8]	8 [4;12]	0.025
Number of arousals	60 [44;95]	55 [45;75]	56 [47;107]	0.905
Sleep REM % TST	20 [16;21]	18 [13;23] §	13 [9;15] #	0.067
Sleep N1 % TST	14 [12;20]	14 [7;19]	13 [12;18]	0.497
Sleep N2 % TST	56 [44;63]	58 [45;63]	61 [49;69]	0.273
Sleep N3 % TST	9 [4;14]	13 [7;20]	11 [5;22]	0.122
Micro arousal index	37 [28;53]	26 [21;37]	26 [19;39]	0.150

# Conclusion





# Choix de la Fréquence respiratoire

	Cycles contrôlés <50%	Cycles contrôlés >50%	Mean difference between groups (95% CI)	p-value
<b>3 mois de suivi</b>				
$\Delta \text{PaCO}_2$ (kPa)	-0.1±0.7	-1.0±1.1	0.9 (0.3 - 1.5)	0.003
$\Delta \text{BMI}$ (kg/m <sup>2</sup> )	-0.3±1.5	-2.2±3.2	1.9 (0.2 - 3.6)	0.031
$\Delta \text{ESS}$	-2±5	-8±6	6 (2 - 9)	0.001
$\Delta \text{SRI - summary score}$	3±11	13±12	-10 (-2 - -17)	0.010
$\Delta \text{Mean nocturnal SpO}_2$ (%)	3±6	5±4	-2 (-5 - 1)	0.146
$\Delta \text{Mean nocturnal tcCO}_2$ (kPa)	-0.3±0.8	-0.9±1.2	0.6 (0.0 - 1.3)	0.049